MedTrace Logo

A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

NCT03911128 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-09-02

No results posted yet for this study

Summary

The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised trials included in the study-design.

The pilot study is implemented as a master protocol without study specific interventions, thus as an observational study. The pilot study is for countries/study-groups who intend to join ALLTogether1 (including experimental interventions). For these countries the pilot study is crucial to optimise diagnostics, registration systems, collaborations with vendors, logistics and data-checks before starting the main study.

The study only includes "standard of care" treatment included in the master protocol.

Conditions

  • Leukemia, Acute Lymphoblastic

Interventions

OTHER

Observational

Observational study - no intervention

Sponsors & Collaborators

  • Nordic Society for Pediatric Hematology and Oncology

    collaborator OTHER

  • The Swedish Childhood Cancer Foundation

    collaborator UNKNOWN

  • NordForsk

    collaborator UNKNOWN

  • Mats Heyman

    lead OTHER

Principal Investigators

  • Mats Heyman, M.D. PhD · Karolinska University Hospital

Eligibility

Min Age
0 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-29
Primary Completion
2033-06-30
Completion
2033-06-30

Countries

  • Denmark
  • Estonia
  • Finland
  • Iceland
  • Lithuania
  • Norway
  • Spain
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03911128 on ClinicalTrials.gov